• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    Novel peptidyl-arginine aldehyde derivatives and their salts of formula I, <IMAGE> wherein X represents a hydrogen atom, benzoyl or tert-butyloxycarbonyl group, and Y is a D-phenylalanine, beta -phenyl-D-lactic acid or D-allo-isoleucine moiety, are prepared from peptidyl-arginine aldehydes protected by an urethane type protecting group on their N- or O-terminal and/or a guanidino group, by removing the protecting group in a mixture of lower alkanols and water by means of hydrogenolysis, and eventually converting the product formed into a salt. The compounds of formula I possess valuable antithrombin activity.
    公开号:SU1366062A3
    申请号:SU802861956
    申请日:1980-01-03
    公开日:1988-01-07
    发明作者:Shandor Bajyus；Erzhebet Sell；Eva Barabash；Daniel Bagd
    申请人:Richter Gedeon Vegyeszet；
    IPC主号:
    专利说明:

    The invention relates to derivatives of peptides, in particular the preparation of derivatives of peptidyl--carboxy-arginine-aldehyde (PKA) of the general formula (0.5 HCl) n'X-O-Pbe-b-Pro-ΝΗ-CH-C (OH) - К-С (= НН) -ИН-С (О) ОН д = д (0,5 НС1) п · Х-О-ПЬе-Ь-Рго-ΝΗ-banks (сн = о) -сн 2 -сн 2 -sn 2 -in-с (= ΝΗ) -IN-С (О) OH, where n = 0 or 1, if
    X is H, and n = 0 if X is tert-butyloxycarbonyl, which can be used in experimental biology and medicine. The goal is to create more active and low-toxic substances of the specified class. Their synthesis is carried out by hydrogenolysis of a compound of the general formula X ^ -D-PbE-b-Pgo--CH (CH = O) - (CH g ) 3 -ΝΗ-C (= ΝΗ) -ΝΗ-C (0) -O- CH ^ -C 2 H 5 , where X, is benzyloxycarbonyl or tert-butyloxycarbonyl. The process is carried out in a mixture of lower alcohol (ethanol) and water (3: 1 ratio) in the presence of an RD / C catalyst. The selection of the target PKA lead either in free form or in the form of chloride. Gross-la; :
    a) С 2 , Н ^ 6 0 5 1,5 Н 2 0; (-) 122-124 °;
    b) С 26 Н 30 Ы 6 0 7 Н 2 0; (-) 63-65 °. New substances increase the clotting time of thrombin-induced fibronogen 10-fold, and the prothrombin activity does not change for 20 hours in a buffer solution with a pH of 7.4, LO = 1200 mg / kg. 1 tab.
    z. 1366062
    >
    CH
    2
    1 1366062
    The invention relates to the method of -Y & -carboxy-arginine ~ aldehydes for the preparation of new chemical compounds of the formula
    Nin, namely derivatives of peptidyl (0.5HC1) l XP-Pbe - b-Ρνο-ΝΗ-ΟΗ ^. 'ΝОН
    WITH
    Ush-eoon
    , about
    (0.5HC1) p -X-B-pebe-E-Pro-1Sh- CH ΊΝΉ ~ <λ
    is clear
    ΝΗ-COOH
    where η is 0, 1, if X is hydrogen and η is 0, if X is tert-butyloxycarbonyl, which can be used in experimental biology and medicine,
    The purpose of the invention is the synthesis of new
    peptidyl-arginine-aldehyde derivatives with higher antithrombin activity in combination
    with low toxicity.
    Example 1. O-Phenylalanil-b.
    -prolyl-кар -carboxy-b-arginine-aldehyde (C-Pbe-b-Pro-b-Ag (COOH) -H).
    Stage 1. tert-Butyloxycarbonyl-б -benzyloxycarbonyl-b-arginine lactam.
    41.1 g (125.0 mmol) of tert-butyloxycarbonyl-b-arginine hydrate are dissolved in 125 ml of 4 n. solution of sodium hydroxide, the solution is cooled to -5 - 0 ° C and with vigorous stirring mixed with 75.0 ml (0.5 mol) of benzyl ester of chlorogolic acid and 125 ml of 4 n. sodium hydroxide solution, the reaction mixture is stirred for 1.5 hours at 0 ° C, then diluted with 100 ml of water, extracted with ether (3x100 ml) and acidified with chilled to 4-6 ° СЗн. with cooling with ice water to pH 3. The precipitate is extracted with ethyl acetate (3x250 ml), the combined ethyl acetate extract is washed with 15% sodium chloride solution (2x125 ml), dried over anhydrous sodium sulfate and evaporated in vacuo. The residue is triturated with ether, filtered off, washed with ether and dried in air.
    In the end, get 37.5 g ( 7 6%)
    25 tert-butyloxycarbonyl-б -benzyloxycarbonyl-b-arginine, K | 0.170.27 "Silica gel C" · Reanal (BHP); ethyl acetate-pyridine-acetic acid plant, 240: 20: 6: 11).
    30 The resulting product is dissolved in 130 ml of tetrahydrofuran, the solution is mixed with 13.58 ml (97 mmol) of triethylamine, cooled to -10 ° C, and 12.8 ml (97 mmol) of isobumin 35 of typical chloroic acid ester are added. The reaction mixture is stirred for 5 minutes and 13.6 ml (97.8 mmol of triethylamine) are added. The mixture is stirred for another 1 hour at 0 ° C and 1 hour without cooling, and it is poured into 600 ml of ice-cold water. The precipitate is filtered off, washed with water and dried vacuum over Ρ ^, Ος.
    In the end, get 32,7 ^ g (91%) tert-butyloxycarbonyl-б-benzyl-oxycarboxylic-b-arginine-lactam with so pl. 162-164 ° C; B. 0.85-0.95
    "Silica gel C’ ’Reanal (WNR); ethyl acetate-pyridine-acetic acid-water, 480: 20: 6: 11),
    Stage 2. Benzyloxycarbonyl-0-phenylalanyl-L-prolyl-S-benzyloxycarbonide-L-arginine-lactam.
    8.6 g (22 mmol) 'tert-butyloxycarbonyl-Ν ° -benzyloxycarbonyl-L55 -arginine-lactam is suspended in 20 ml
    ethyl acetate and with stirring when
    5 ° C is mixed with 40 ml of 4 M solution
    HC1 in ethyl acetate. Reaction mixture
    stirred for 30 minutes while cooling
    3 1366062
    four
    ice water and diluted with 100 ml of chilled ethyl acetate. The precipitate is filtered off, washed with ethyl acetate and dried in vacuum over potassium hydroxide. The resulting product is dissolved in 20 ml of dimethylformamide, the solution is cooled to -10 ° C and mixed with 6.2 ml (44 mmol) of triethylamine. The resulting suspension is injected into the interaction with mixed anhydride obtained in this way.
    8.0 g (200 mmol) of benzyloxycarbonyl-O-phenylalanine-L-proline are dissolved in 25 ml of dimethylformamide, the solution is cooled to -15 ° C and mixed with 2.22 ml (20 mmol) of α-methylmorpholine and 2.64 ml (20 mmol) isobutyl chlorotic acid ester. The reaction mixture is stirred for 10 minutes, and then the suspension is added and the reaction mixture is adjusted to pH 8-9 by the addition of triethylamine. The reaction mixture is stirred for 1 hour at -15 ° C and for another 1 hour at 0 ° C, then diluted with 50 ml of benzene. The precipitation is filtered off, washed with benzene (2x20 ml). 50 ml of water are added to the combined filtrate, the phases are separated and the aqueous phase is extracted with benzene (3x20 ml). The benzene extract is washed with 10% aqueous solution of sodium carbonate, 30 ml of water, 0.1 n. hydrochloric acid (2x 30 ml), water (2x30 ml), dried over anhydrous sodium sulfate and evaporated in vacuo. The residue is triturated with 30 ml of ether, the ether is decanted, the residue is triturated with petroleum ether, the precipitate is filtered off, washed with petroleum ether and dried in air.
    A total of 11.7 g (87%) of benzyloxycarbonyl-O-phenylalanyl are obtained.
    -L-prolyl-Ν -benzyloxycarbonyl-b-arginine-lactam, 0.72-0.78
    Silica gel S Reanal (Hungary); ethyl acetate-pyridine-acetic acid-water; 480: 20: 6: 11).
    Stage 3. Benzyloxycarbonyl-C
    -phenylalanyl-b-prolyl-s-benzyloxycarbonyl-b-arginine-aldehyde.
    10.05 g (15 mmol) of benzyloxycarbonyl-O-phenylalanyl-L-prolyl-A, -benzyloxycarbonip-b-arginine-lactam is dissolved in 45 ml of tetrahydrofuran, the solution is cooled to -20 with C and with vigorous stirring
    35
    ten
    15
    20
    thirty
    40
    45
    50
    55
    sew with 28 ml of a 0.4 M solution of lithium aluminum hydride (I I, 25 mmol) in tetrahydrofuran. The progress of the reaction is controlled by thin layer chromatography.
    After completion of the reaction, the reaction mixture is carefully acidified with 1N. hydrochloric acid to pH 2 and diluted with 100 ml of water, extracted with n-hexane (2 x 30 ml) and dichloromethane (3 x 30 ml), the combined dichloromethane extract is washed with 10% aqueous sodium carbonate solution (3x10 ml) and water (2x10 ml), dried over anhydrous sodium sulfate and evaporated in vacuo. The residue is dissolved in 50 ml of benzene and the solution is evaporated in vacuo. This operation is repeated twice more. The residue is triturated with ether, the precipitate is filtered off, washed with ether and dried in air.
    As a result, 7.3 g (72%) of benzyloxycarbonyl-O-phenylalanil-L-prolyl-H-benzyloxycarbonyl-b-argnene-aldehyde, K 0.32-0.40 (Silane gel Reanal (WHP); ethyl acetate-pyridine-acetic acid-water, 480:: 20: 6: 11), so pl. 116-117 ° C.
    Stage 4. β-Phenylalanil-b-prolyl-c-carboxy-b-arginine-aldehyde.
    6.7 g (10 mmol) of benzyloxycarbonyl-O-phenylalanyl-L-prolyl-A-benzyloxycarbonyl-L-arginine-aldehyde is dissolved in 100 ml of 75% aqueous ethanol. 1 g of 10% palladium on activated carbon is added to the solution and subjected to hydrogenolysis at normal pressure. The progress of the reaction is controlled by thin layer chromatography in the ethyl acetate-pyridine-acetic acid-water system, 30: 20: 6: 11. After the end of the reaction, the catalyst is filtered off, washed with 30 mp of water. The combined filtrate to remove ethanol was evaporated in vacuo. The residue is diluted with 100 ml of water, extracted with 30 ml of dichloromethane, frozen and lyophilized.
    In the end, get 4.3 g of-phenylS
    alanyl-b-prolyl-n-carboxy ~ b-arginine-aldehyde, [s <) - 123 ° C (C1; found,%: C 52.21; H 7.00;
    N 17.89.
    1.5 H 2 O
    Calculated,%: C, 53.28; H 6.97;
    N 17.80.
    Amino acid analysis: Pby 1.02 (1); Ag§-H 0.97 (1); Pro 1.00 (1).
    5 1366062
    6
    Excreted with sulfuric acid CO / 10.9%; C0 7 , precipitated in the form of VASO $ 2.1%. B. £ 0.35-0.40 (Silica gel C, ethyl acetate-pyridine-acetic acid-water, 30: 20: 6: 11).
    Example 2. ϋ-Phenylalanilide
    -L-prolyl-Ν “-carboxy-b-arginine-aldehyde incomplete hydrochloride (Η-ϋ-Ple-b-Pro-b-Ag § (COOH) -H 0.5HC1).
    0.48 g of α-phenylalanyl-L-prolyl-I ^ -carboxy-b-arginine-aldehyde is dissolved in 5 ml of water, the solution is cooled to 3-5 a C, and then mixed at this temperature with 5 mp 0.1 n . of hydrochloric acid. The mixture is frozen and lyophilized. In the end, get 0.45 g of incomplete hydrochloride ф-Fe (l
    nilalanil-b-prolyl-n-carboxy-arginine-aldehyde cGs13 ^ 0 = -120 ° (C 1; water); 0.35-0.40 (Silica gel C; ethyl acetate-pyridine-acetic acid-water, 30: 20: 6: 11).
    Found,%: C 52.86; H 6.95;
    N 17.69; C1 3.62.
    С Н ЯД- 0,5НС1 · 0,5Н „0
    Calculated,%: C 53.24; H 6.70;
    N 17.74; C1 3.74,
    Example 3. tert-Butyloxycarbonyl-O-phenylalanyl-L-prolyl-кар-carboxy-b-arginine-aldehyde,
    Stage 1. tert-Butyloxycarbonyl-O-phenylalanyl-L-prolyl-H ^ -benzyloxycarbonyl-b-arginine-lactam.
    8.6 g (22 mmol) of tert-butyloxycarbonyl-Ν ^ -benzyloxycarbonyl-b-arginine-lactam are converted into N -benzyloxycarbonyl-arginine-lactam of example 1 (step 2), which, as a suspension, in dimethylformamide is reacted with mixed anhydride obtained in this way.
    7.25 g (20 mmol) of tert-butyloxycarbonyl-B-phenylalanyl-proline and 2.22 ml (20 mmol) of α-methidmorpholine are dissolved in 20 ml of dimethylformamide. The solution is cooled to -15 ° C and at this temperature, 2.64 ml (20 mmol) of chlorobolic acid isobutyl ester are added vigorously while the indicated suspension is added after 5 min. The reaction mixture is stirred for 1 hour at -15 ° C and for another 1 hour at 0 ° C and diluted with 30 ml of benzene. The precipitation is filtered off, washed with benzene (2x10 ml). The combined filtrate is mixed with 50 ml of water and the phases are separated. Waterway
    the phase is extracted with benzene (2x10 ml) and the benzene extract is combined with the benzene phase. The combined benzene extract is washed with 10% sodium carbonate solution (3x30 ml), water (1x30 ml), 0.5 n. sulfuric acid (3x30 ml) and again with water (3x30 ml), dried over anhydrous sodium sulfate and evaporated in vacuo. The residue is triturated with petroleum ether, the precipitate is filtered off, washed with petroleum ether and dried in air.
    15 In the end, 9.65 g (76%) of tert-butyloxycarbonyl-B-phenyl-alanyl-L-prolyl-Ν ( ′ -benzyloxycyoaconon-b-arginine-lactam. 0.81–0.89
    ("Silica gel C" Reanal (VNR); ethyl ", acetate-pyridine-acetic acid-water, 480: 20: 6: 1 1).
    Stage 2. tert-Butyloxycarbonyl-B-phenylalanyl ~ L-prolyl-H ( '' -benzyloxycarbonyl-L-arginine-aldehyde.
    wasp 9.52 g (15 mmol) tert-butyloxycarbonyl-b-phenylalanyl-b-prolyl-β-benzyloxycarbonyl-b-arginine-lactam is reacted with lithium aluminum hydride in example 1 (stage 3) with the difference that after the end of the reaction the reaction mixture is acidified with 0.5 n. sulfuric acid.
    The result is 6.9 g (72%)
    't r e t-butyl to sik ar b onyl-B-phenyl-alanyl-b-prolyl-1-benzyloxycarbonyl35-b-arginine-aldehyde c 0.46-0.56 (Silica gel C, Reanal (BHP) ethyl acetate-pyridine-acetic acid-water, 240: 20: 6: 11).
    4 θ Stage 3. tert-Butyloxycarbonyl-B-phenyl alanyl-b-prolyl-C “- carboxy-b-arginine-aldehyde.
    6.4 g (10 mmol) tert-butyloxycarbonyl-O-phenylalanyl-b-prolyl-Ν -benzyloxycarbonyl-b-arginine-alde45
    the guide is subjected to the hydrogenolysis of example 1 (stage 4).
    A total of 5.1 g (85%) of tert-butyloxycarbonyl-B-phenyl-alanyl-L-prolyl-5-carboxy-b-arginine 50 aldehyde is obtained with [^ 1 ^ ° = -64 + 1 ° (C 1; in an aqueous solution with a pH of 7, fixed with hydrochloric acid). 0.460.56 ("Silica gel C" Reanal (BHP) ;, ethyl acetate-pyridine-acetic acid 55 water, 30: 20: 6: 11).
    Found,%: C 55.1; H 6.90;
    N 15.10.
    С ^ Н ^ О, Н 0
    Calculated,%: C 55.31; H 6.79; N14.90.
    Excreted with sulfuric acid CO ^ 10.1%, precipitated in the form of BaCO 3.1%. Amino acid analysis: PH 0.96 (1); Ag§-H 0.97 (defined as ΝΗ 3 ); Pro 1.00 (1).
    The antithrombin activity of the proposed compounds was studied in experiments with ϊη νΪΡΓο in the ability to increase the clotting time of fibrinogen induced by thrombin. The study was conducted in comparison with known compounds possessing anti-thrombin activity (H-O-PHHe-b-Pro-Ar £ £ -H · HC1 and ϋ-PHHe-b-Pro-Agu-H * x 2C1CUNC).
    In the experiment, 0.2 ml of 0.5% bovine fibrinogen in 0.9% sodium chloride solution was used; 0.1 ml of Tris / HC1 buffer (pH 7.4) in which the test compound was dissolved; 0, I ml, 5 U / ml solution of the US standard of human thrombin (ΝΙΗ, WebNoLess Maryland, USA). The fibrinogen coagulation time in this system without the addition of inherited peptides is 15 s.
    The antithrombin activity of the peptides was determined by the concentration of the substance, which is necessary to increase the clotting time of fibrinogen, induced by thrombin, 10 times. The antithrombin activity was determined immediately after preparation of the solution of the test compound in Tris / HC1 buffer (pH 7.4) and after 20 h. Activity 1) -PHe-b-Pro-b-Arg (COOH) -H is 100% accepted.
    The results obtained are presented in the table.
    As can be seen from the data in the table, the proposed compounds are superior in antithrombin activity known and retain their
    366062 8
    the activity is almost unchanged for 20 h in a buffer solution with a pH of 7.4, while the activity of known compounds in these conditions is reduced by 10-20%.
    ten
    20
    25
    thirty
    35
    40
    45
    In addition, in the ΐπ νίνο ^ experiments, the antithrombin activity of compounds of the general formula was studied in the example of O-phenylalanil-L-prolyl-H-carboxy-L-arginine-aldehyde. Studies were conducted on mice, rats, rabbits, dogs and monkeys. As a result of the research, it was established that ϋ-phenylalanil-L-prolyl-б-carboxy-b-arginine-aldehyde has antithrombin activity not only when administered intravenously, intramuscularly and subcutaneously, but also when administered orally. When administered to dogs in doses (= 50 mg / kg of ф-phenylalanil-b-prolyl-кар-carboxy-b-arginine-aldehyde, orally causes an increase in blood clotting time by 4-6 times. The blood clotting time is measured on a thromboelastograph (1/4) Austria). Known compounds when administered orally in doses of 50 mg / kg had virtually no effect on blood clotting time.
    The acute toxicity of compounds of the general formula has been studied in mice.
    As a result of the research conducted, it was established that these compounds are of low toxicity: for P-PHH-b-Pro-B-Arg (COOH) -H 113 ^ = 1200 mg / kg, and for Vos-P-PH-B-B-Pro-B B-Ag§ (COOH) -N 1300 mg / kg.
    权利要求:
    Claims (1)
    [1]
    Claim
    The method of obtaining peptidyl-α-carboxy-arginine-allegide derivatives of the general formula
    (О, 5НС1) П Х-Ό-РНе-Ь-Рго-Н-СН Н ~ С
    I Υ "ta-soon n
    he
    NN
    (0.5Η0ΐ) η ·-ϋ-PHHe-b ~ Po-HH “CH HH-C ^
    but HH- WITH OH
    9 1366062 10
    where η = 0, 1, if X is hydrogen and characterized in that
    η = 0 if X is a tert-butyl compound of the general formula
    hydroxycarbonyl,
    Η'Ί Ζ ΜΗ
    X ^ B-Pye-E-Pro-ΝΗ-CH N11-, CHO ™ -C-OCH 2 C in H 8
    θ
    where X] is benzyloxycarbonyl, tert-lower alcohol and water in bulk
    butyloxycarbonyl, a ratio of 3: 1, followed by removal of the target products with catalytic hydrogel
    nolysis in the presence of Ρά / C in a mixture of 15 form or in the form of chlorohydrates.
    Example Compound The amount of substance required to increase the clotting time of fibrinogen induced by thrombin,10 times µg / ml directly 'after dissolving the compound through 20 h mcg / ml Relative activity,% mcg / ml Relativeactivity,% one P-Pye-b-Pro-b-Agu (COOH) -N 0-, 275 100 0,300 92 2 0-Pye-b-Pro-b-Ag Аг (C00H) -N 0.5HS1 0.050 550 0.350 79 3 Boc-0-Ple-b-Pro-b-Ag ((COOH) -H 0.425 . 65 0.450 61 ϋ-PHE-L-Rgo-L-Age-N · HC1 0.35-0.95 79-29 6.0 five O-Pye-L-Pro-L-Agu-H · 2CH 3 COOH 0.37-1.25 73-22 6.2 four
    类似技术:
    公开号 | 公开日 | 专利标题
    SU1366062A3|1988-01-07|Method of obtaining derivatives of peptidyl-ng-caroxy-arginin-aldehydes
    KR850001269B1|1985-09-04|Process for preparing aminoacid derivatives
    CA1177488A|1984-11-06|Amidine compound, process for producing same and anti- complement agent comprising same
    AU606901B2|1991-02-21|Novel phosphinic acid derivatives
    US5055451A|1991-10-08|Aryloxy and arylacyloxy methyl ketones as thiol protease inhibitors
    US6864249B2|2005-03-08|Piperidine and azetidine thrombin inhibitors
    JPH11503455A|1999-03-26|Thrombin inhibitor
    JP2001512713A|2001-08-28|Aryloxyarylsulfonylaminohydroxamic acid derivatives
    JP2000512616A|2000-09-26|Pyridinone thrombin inhibitor
    JPH11511124A|1999-09-28|Cell adhesion inhibitor
    JP2844329B2|1999-01-06|Selective thrombin inhibitors
    EP1157998B1|2004-02-11|Heterocyclic compounds, intermediates thereof and elastase inhibitors
    RU2178419C2|2002-01-20|Serine protease inhibitors
    US5158936A|1992-10-27|Aryloxy and arylacyloxy methyl ketones as thiol protease inhibitors
    EP0743953B1|1998-12-02|Diastereomeric pure trifluoromethyl ketone peptide derivatives as inhibitors of human leukocyte elastase
    US6300337B1|2001-10-09|Acetamide derivative and use thereof
    KR870001087B1|1987-06-04|Process for the preparation of amidine compounds
    JPH10500992A|1998-01-27|New elastase inhibitors
    CA2212356A1|1996-10-17|Novel 4-substituted-3-peptidyl-azetidin-2-one derivatives useful as cysteine proteinase inhibitor
    EP0121830A2|1984-10-17|Substituted dipeptides as antihypertensives
    AU750561B2|2002-07-25|Amino acid amidinohydrazones, alkoxyguanidines and aminoguanidines as protease inhibitors
    JP2659990B2|1997-09-30|Crystalline quinapril and its production
    JP2003509409A|2003-03-11|Azacycloalkanone serine protease inhibitor
    WO1997012904A1|1997-04-10|Polyfluoroalkyl tryptophan tripeptide thrombin inhibitors
    IE59174B1|1994-01-26|Heptanoyl-glu-asp-ala-amino acid immunostimulants
    同族专利:
    公开号 | 公开日
    DK3880A|1980-07-05|
    DE3000225A1|1980-07-24|
    IT7928304D0|1979-12-21|
    FI67539B|1984-12-31|
    JPS55122749A|1980-09-20|
    HU177098B|1981-07-28|
    NO151085C|1985-02-06|
    SE448461B|1987-02-23|
    NL8000040A|1980-07-08|
    US4316889A|1982-02-23|
    SE8000032L|1980-07-05|
    FR2445826B1|1984-11-23|
    AT372076B|1983-08-25|
    CH643820A5|1984-06-29|
    FI800008A|1980-07-05|
    DK149895C|1987-04-21|
    IL58978A|1982-09-30|
    NL191537B|1995-05-01|
    CA1133897A|1982-10-19|
    ZA796895B|1980-12-31|
    IT1166917B|1987-05-06|
    ATA1280A|1983-01-15|
    NO151085B|1984-10-29|
    DE3000225C2|1989-10-19|
    IL58978D0|1980-03-31|
    ES487464A0|1980-11-01|
    DK149895B|1986-10-20|
    FI67539C|1985-04-10|
    BE880844A|1980-06-24|
    NL191537C|1995-09-04|
    NO794327L|1980-07-07|
    ES8100252A1|1980-11-01|
    AU5420779A|1980-07-10|
    FR2445826A1|1980-08-01|
    JPS5951936B2|1984-12-17|
    AU533343B2|1983-11-17|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    JPS4941418A|1972-08-29|1974-04-18|
    HU169870B|1974-06-14|1977-02-28|
    JP4222115B2|2003-06-13|2009-02-12|セイコーエプソン株式会社|Non-contact power transmission device|HU178398B|1979-06-12|1982-04-28|Gyogyszerkutato Intezet|Process for producing new agmatine derivatives of activity against haemagglutination|
    JPH02342B2|1980-09-19|1990-01-08|Nippon Kayaku Kk|
    HU184368B|1981-01-13|1984-08-28|Gyogyszerkutato Intezet|Process for preparing d-phenyl-alanyl-l-propyl-l-arginine-ald ehyde-shulphate|
    DE3481913D1|1983-04-27|1990-05-17|Ici America Inc|PROLIN DERIVATIVES.|
    HU192646B|1984-12-21|1987-06-29|Gyogyszerkutato Intezet|Process for preparing new n-alkyl-peptide aldehydes|
    JPH0312905Y2|1984-12-21|1991-03-26|
    JPH0536046Y2|1987-09-09|1993-09-13|
    US5736520A|1988-10-07|1998-04-07|Merrell Pharmaceuticals Inc.|Peptidase inhibitors|
    ZA897515B|1988-10-07|1990-06-27|Merrell Dow Pharma|Novel peptidase inhibitors|
    JPH0277227U|1988-11-30|1990-06-13|
    US5430023A|1990-09-28|1995-07-04|Eli Lilly And Company|Tripeptide antithrombotic agents|
    CA2075154A1|1991-08-06|1993-02-07|Neelakantan Balasubramanian|Peptide aldehydes as antithrombotic agents|
    US5252566A|1991-11-12|1993-10-12|Eli Lilly And Company|Antithrombotic agents|
    US5416093A|1991-11-12|1995-05-16|Eli Lilly And Company|Antithrombotic agents|
    JPH08501057A|1992-03-04|1996-02-06|ヂョヂセルクタトーインテーゼットカーエフテー|Novel anticoagulant factor peptide derivative, pharmaceutical composition containing the same, and method for producing the same|
    AU675981B2|1992-12-02|1997-02-27|Bristol-Myers Squibb Company|Guanidinyl-substituted heterocyclic thrombin inhibitors|
    US5583146A|1992-12-02|1996-12-10|Bristol-Myers Squibb Company|Heterocyclic thrombin inhibitors|
    IL108031D0|1992-12-22|1994-04-12|Procter & Gamble|Difluoro pentapeptide derivatives and pharmaceutical compositions containing them|
    US5488037A|1994-03-04|1996-01-30|Eli Lilly And Company|Antithrombotic agents|
    US5914319A|1995-02-27|1999-06-22|Eli Lilly And Company|Antithrombotic agents|
    CA2143533A1|1994-03-04|1995-09-05|Kenneth D. Kurz|Antithrombotic agents|
    US5602101A|1994-03-04|1997-02-11|Eli Lilly And Company|Antithrombotic agents|
    US5439888A|1994-03-04|1995-08-08|Eli Lilly And Company|Antithrombotic agents|
    US5710130A|1995-02-27|1998-01-20|Eli Lilly And Company|Antithrombotic agents|
    US5726159A|1994-03-04|1998-03-10|Eli Lilly And Company|Antithrombotic agents|
    US5885967A|1994-03-04|1999-03-23|Eli Lilly And Company|Antithrombotic agents|
    US5707966A|1994-03-04|1998-01-13|Eli Lilly And Company|Antithrombotic agents|
    US5484772A|1994-03-04|1996-01-16|Eli Lilly And Company|Antithrombotic agents|
    US5436229A|1994-03-04|1995-07-25|Eli Lilly And Company|Bisulfite adducts of arginine aldehydes|
    ZA951618B|1994-03-04|1996-08-27|Lilly Co Eli|Antithrombotic agents|
    US5705487A|1994-03-04|1998-01-06|Eli Lilly And Company|Antithrombotic agents|
    US5637599A|1994-06-17|1997-06-10|Corvas International, Inc.|Arginine mimic derivatives as enzyme inhibitors|
    NZ289562A|1994-06-17|1998-10-28|Corvas Int Inc|Solution phase and solid phase methods for the synthesis of peptidyl argininal derivatives and salts thereof|
    US5514777A|1994-06-17|1996-05-07|Corvas International, Inc.|Methods of synthesis of peptidyl argininals|
    US5721214A|1995-06-07|1998-02-24|Cor Therapeutics, Inc.|Inhibitors of factor Xa|
    US6245743B1|1996-06-05|2001-06-12|Cor Therapeutics, Inc.|Inhibitors of factor Xa|
    US6069130A|1995-06-07|2000-05-30|Cor Therapeutics, Inc.|Ketoheterocyclic inhibitors of factor Xa|
    US5919765A|1995-06-07|1999-07-06|Cor Therapeutics, Inc.|Inhibitors of factor XA|
    US6046169A|1995-06-07|2000-04-04|Cor Therapeutics, Inc.|Inhibitors of factor XA|
    US6022861A|1995-06-07|2000-02-08|Cor Therapeutics, Inc.|Ketoheterocyclic inhibitors of factor Xa|
    JP2000503010A|1995-12-29|2000-03-14|スリー―ダイメンショナル・ファーマスーティカルス・インコーポレーテッド|Amidino protease inhibitor|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    HU79GO1435A|HU177098B|1979-01-04|1979-01-04|Process for producing new peptidyl-n-carboxy-l-arginin-a|
    [返回顶部]